27916455|t|Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models
27916455|a|Huntington's disease (HD) symptoms are driven to a large extent by dysfunction of the basal ganglia circuitry. HD patients exhibit reduced striatal phoshodiesterase 10 (PDE10) levels. Using HD mouse models that exhibit reduced PDE10, we demonstrate the benefit of pharmacologic PDE10 inhibition to acutely correct basal ganglia circuitry deficits. PDE10 inhibition restored corticostriatal input and boosted cortically driven indirect pathway activity. Cyclic nucleotide signaling is impaired in HD models, and PDE10 loss may represent a homeostatic adaptation to maintain signaling. Elevation of both cAMP and cGMP by PDE10 inhibition was required for rescue. Phosphoproteomic profiling of striatum in response to PDE10 inhibition highlighted plausible neural substrates responsible for the improvement. Early chronic PDE10 inhibition in Q175 mice showed improvements beyond those seen with acute administration after symptom onset, including partial reversal of striatal deregulated transcripts and the prevention of the emergence of HD neurophysiological deficits. VIDEO ABSTRACT.
27916455	0	21	Phosphodiesterase 10A	T103	UMLS:C1452465
27916455	42	63	Cortico-Basal Ganglia	T017	UMLS:C0004781
27916455	64	72	Function	T038	UMLS:C0031843
27916455	76	96	Huntington's Disease	T038	UMLS:C0020179
27916455	97	103	Models	T038	UMLS:C0012644
27916455	104	124	Huntington's disease	T038	UMLS:C0020179
27916455	126	128	HD	T038	UMLS:C0020179
27916455	130	138	symptoms	T033	UMLS:C1457887
27916455	190	203	basal ganglia	T017	UMLS:C0004781
27916455	215	217	HD	T038	UMLS:C0020179
27916455	243	271	striatal phoshodiesterase 10	T103	UMLS:C1447737
27916455	273	278	PDE10	T103	UMLS:C1447737
27916455	294	296	HD	T038	UMLS:C0020179
27916455	297	309	mouse models	T038	UMLS:C2986594
27916455	331	336	PDE10	T103	UMLS:C1452465
27916455	382	387	PDE10	T103	UMLS:C1452465
27916455	418	431	basal ganglia	T017	UMLS:C0004781
27916455	452	457	PDE10	T103	UMLS:C1452465
27916455	478	493	corticostriatal	T017	UMLS:C0229962
27916455	557	584	Cyclic nucleotide signaling	T038	UMLS:C1155588
27916455	600	602	HD	T038	UMLS:C0020179
27916455	603	609	models	T038	UMLS:C0012644
27916455	615	620	PDE10	T103	UMLS:C1452465
27916455	642	653	homeostatic	T038	UMLS:C0019868
27916455	654	664	adaptation	T038	UMLS:C0392673
27916455	677	686	signaling	T038	UMLS:C3537152
27916455	688	697	Elevation	T058	UMLS:C0439775
27916455	706	710	cAMP	T103	UMLS:C0001455
27916455	715	719	cGMP	T103	UMLS:C0018338
27916455	723	728	PDE10	T103	UMLS:C1452465
27916455	765	791	Phosphoproteomic profiling	T058	UMLS:C1327760
27916455	795	803	striatum	T017	UMLS:C0229962
27916455	819	824	PDE10	T103	UMLS:C1452465
27916455	923	928	PDE10	T103	UMLS:C1452465
27916455	943	952	Q175 mice	T038	UMLS:C2986594
27916455	1002	1016	administration	T058	UMLS:C1533734
27916455	1023	1030	symptom	T033	UMLS:C1457887
27916455	1068	1076	striatal	T017	UMLS:C0229962
27916455	1089	1100	transcripts	T103	UMLS:C1519595
27916455	1140	1142	HD	T038	UMLS:C0020179
27916455	1143	1161	neurophysiological	T038	UMLS:C1327471